Table of Contents

company-logo

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma Dividend Announcement

• MEI Pharma announced a annually dividend of $1.75 per ordinary share which will be made payable on 2023-12-06. Ex dividend date: 2023-11-16
• MEI Pharma's trailing twelve-month (TTM) dividend yield is 55.91%
• MEI Pharma's payout ratio for the trailing twelve months (TTM) is 131.23%

MEI Pharma Dividend History

Ex-Div dateDividend amountDividend typePay date
2023-11-16$1.75annually2023-12-06

MEI Pharma Dividend per year

MEI Pharma Dividend Yield

MEI Pharma current trailing twelve-month (TTM) dividend yield is 55.91%. Interested in purchasing MEI Pharma stock? Use our calculator to estimate your expected dividend yield:

MEI Pharma Financial Ratios

P/E ratio1.17
PEG ratio-1.83
P/B ratio0.63
ROE31.61%
Payout ratio131.23%
Current ratio4.88
Quick ratio4.88
Cash Ratio0.44

MEI Pharma Dividend FAQ

Does MEI Pharma stock pay dividends?
MEI Pharma does not currently pay dividends to its shareholders.
Has MEI Pharma ever paid a dividend?
No, MEI Pharma has no a history of paying dividends to its shareholders. MEI Pharma is not known for its dividend payments.
Why doesn't MEI Pharma pay dividends?
There are several potential reasons why MEI Pharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will MEI Pharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While MEI Pharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is MEI Pharma a dividend aristocrat?
MEI Pharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is MEI Pharma a dividend king?
MEI Pharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is MEI Pharma a dividend stock?
No, MEI Pharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy MEI Pharma stocks?
To buy MEI Pharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy MEI Pharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.